FDA 483 OBSERVATION · #346 OF 1,932 MOST-CITED

Informed consent

FDA cited this observation 81 times across 81 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Bioresearch Monitoring68
Biologics13
BY FISCAL YEAR
FY20263
FY20259
FY20245
FY202310
FY20227
FY20216
FY20204
FY201912
FY20188
FY201711
FY20166

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.6× the rate of the average FDA-cited firm (12.3% vs 7.8%), across 81 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Failure to obtain informed consent in accordance with 21 CFR Part 50 from each human subject prior to conducting study-related tests.

Manohar L. Jethani, MD · Oak Brook, Illinois · Bioresearch Monitoring · 2026-02-05

Failure of the responsible physician to explain the risks and hazards of the procedure to the donor.

American National Red Cross · Lehi, Utah · Biologics · 2025-12-10

Failure to obtain informed consent in accordance with 21 CFR Part 50 from each human subject prior to drug administration and conducting study-related tests.

David S. Krakow, M.D. · Mount Kisco, New York · Bioresearch Monitoring · 2025-11-21

Failure to obtain informed consent in accordance with 21 CFR Part 50 from each human subject prior to conducting study-related tests.

Adam I. Frome, MD · Shenandoah, Texas · Bioresearch Monitoring · 2025-08-18

Failure to obtain informed consent in accordance with 21 CFR Part 50 from each human subject prior to drug administration and conducting study-related tests.

Paul Schulz, M.D. · Houston, Texas · Bioresearch Monitoring · 2025-07-22

Failure to obtain informed consent in accordance with 21 CFR Part 50 from each human subject prior to drug administration and conducting study-related tests.

David Pham, M.D. · Aurora, Colorado · Bioresearch Monitoring · 2025-06-18

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry →GCP discipline →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →